Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization
Dec. 9, 2021—The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which protects against COVID-19, discovered last year at Vanderbilt University Medical Center.
U.S. government reserves supply of COVID-19 antibody cocktail discovered at VUMC
Apr. 6, 2021—The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.
COVID treatment studied by VUMC gains FDA approval
Oct. 26, 2020—Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.
Zantac recalled for carcinogen levels above FDA standards
Nov. 27, 2019—The popular heartburn drug ranitidine, commonly known as Zantac, was voluntarily recalled due to the contamination of a human carcinogen that could potentially cause cancer. The recall includes oral tablets, capsules, and syrup.
VUMC assumes new role in FDA safety monitoring
Oct. 16, 2019—Vanderbilt University Medical Center is assuming an expanded role in U.S. Food and Drug Administration (FDA) medical product safety monitoring.
Treatment approved for patients with acute graft-versus-host disease
Jun. 13, 2019—The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC's Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.
Apr. 26, 2018—The chair of the U.S. Federal Communications Commission, Ajit Pai, recently visited Allen County Schools in Kentucky to see a demonstration of the new school-based telemedicine program.
Ear Community at the FDA
Mar. 22, 2018—Ron Eavey, MD, Guy M. Maness Professor and chair of Otolaryngology and director of the Vanderbilt Bill Wilkerson Center, far right, testified recently at the Food and Drug Administration in Washington, D.C., along with members of Ear Community.
Medication safety in the ICU
Sep. 19, 2017—Facilitated reporting of medication-related events in the intensive care unit can provide opportunities for optimizing quality of care and patient safety.
Investigational new drug for Alzheimer’s scheduled for first study in humans
Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.
Robotic advances promise artificial legs that emulate healthy limbs
Nov. 7, 2013—Recent advances in robotics technology make it possible to create prosthetics that can duplicate the natural movement of human legs which promises to dramatically improve the mobility of lower-limb amputees.
Pneumonia vaccine for children to be tested in older adults
Oct. 11, 2012—Vanderbilt is taking part in a national study to test in older adults the use of a vaccine designed to protect children against a common cause of pneumonia.